Halozyme Therapeutics Inc. agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on drug delivery.
Halozyme on Wednesday said it would pay $5.60 per share in cash, valuing Antares at roughly $960 million.
